System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Giuseppe Lombardi is an expert in Oncology at Istituto Oncologico Veneto (Italy). As of October 2026, ScienceLeadR ranks Giuseppe Lombardi in the top 1% of experts worldwide for Glioma, Nervous System Neoplasms and Brain Neoplasms. Giuseppe Lombardi has authored 289 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 10 of them ongoing. SLR score: 1,439 (community average: 125). How the SLR is computed.

LeadR Profile

Giuseppe Lombardi Istituto Oncologico Veneto Italy
1 439 ScienceLeadR Reputation 1439

Unlock

Register Login
Network Map

Oncology

Subspecialties: Neurology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Istituto Oncologico Veneto

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 289

Citations

Citations: 6 539 1st author: 64 Last author: 49 Unique author: 1

Main journals

Neuro Oncol 35
J Clin Oncol 26
Cancers (Basel) 22
J Neurooncol 14
J Sex Med 12

Best Journals

J Clin Oncol 13
Lancet Oncol 1
N Engl J Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
AMPK Pathway Activation Markers in GBM: Expression Patterns and Clinical Associations in a Real-World Study.
PMID 42737695 — telepathology, immunohistochemistry, neoplasms, lomustine, biomarkers, glioblastoma, therapeutics		Int J Mol Sci20260
Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).
PMID 42607618 — astrocytoma, neoplasms, glioblastoma		Eur J Cancer20260
ESTRO, ESNR and EORTC consensus-based definition for MRI abnormalities after radiotherapy for intracranial central nervous system tumours.
PMID 42623110 — delphi technique, radiotherapy, brain neoplasms, clinical decision-making, central nervous system, nervous system, medical oncology		Neuro Oncol20260
Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.
PMID 42614980 — bevacizumab, tensins, biomarkers, phosphoric monoester hydrolases, glioblastoma, therapeutics		Neurooncol Adv20260
BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions.
PMID 42261252 — brain neoplasms, glioma, glioblastoma, therapeutics, child		Neuro Oncol20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 8
Phase 2 6
N/A 3
Phase 1 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Recruiting 8
Active not recruiting 5
Completed 3
Unknown 2
Terminated 1
Withdrawn 1

By type:

Interventional 18
Observational 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 2
multicentric5to9 1
multicentricup10 17

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High grade Glioma Following Radiotherapy
2022-502269-13-00 — radiotherapy, glioma, temozolomide, child		Phase 2Active not recruiting2024
A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields) together with temozolomide and pembrolizumab compared to Optune (Tumor Treating Fields) together with temozolomide and placebo (ie inactive substance)
2024-513550-30-00 — research design, temozolomide, neoplasms, maintenance, glioblastoma, therapeutics		Phase 3Recruiting2025
Development of an Artificial Intelligence Model for Optimising Therapy in Gliomas Gliomas
NCT06620055 — intelligence, glioma, algorithms, therapeutics, artificial intelligence		N/ARecruiting2023
EF 41 KEYNOTE D58 Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563 — saline solution, temozolomide, neoplasms, maintenance, solutions, immunotherapy, glioblastoma, therapeutics		Phase 3Recruiting2025
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly diagnosed MGMT Unmethylated Glioblastoma
NCT06388733 — brain neoplasms, safety, temozolomide, pharmaceutical preparations, brain, neoplasms, glioblastoma, therapeutics		Phase 3Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS